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Eight-channel iTRAQ enables comparison of the activity of six
leukemogenic tyrosine kinases
Abstract
There are a number of leukemogenic protein-tyrosine kinases (PTKs) associated with leukemic
transformation. Although each is linked with a specific disease their functional activity poses the
question whether they have a degree of commonality in their effects upon target cells. Exon array
analysis of the effects of six leukemogenic PTKs (BCR/ABL, TEL/PDGFRbeta, FIP1/PDGFRalpha,
D816V KIT, NPM/ALK, and FLT3ITD) revealed few common effects on the transcriptome. It is
apparent, however, that proteome changes are not directly governed by transcriptome changes.
Therefore, we assessed and used a new generation of iTRAQ tagging, enabling eight-channel relative
quantification discovery proteomics, to analyze the effects of these six leukemogenic PTKs. Again these
were found to have disparate effects on the proteome with few common targets. BCR/ABL had the
greatest effect on the proteome and had more effects in common with FIP1/PDGFRalpha. The
proteomic effects of the four type III receptor kinases were relatively remotely related. The only protein
commonly affected was eosinophil-associated ribonuclease 7. Five of six PTKs affected the
motility-related proteins CAPG and vimentin, although this did not correspond to changes in motility.
However, correlation of the proteomics data with that from the exon microarray not only showed poor
levels of correlation between transcript and protein levels but also revealed alternative patterns of
regulation of the CAPG protein by different oncogenes, illustrating the utility of such a combined
approach.
Eight-channel iTRAQ enables comparison of the activity of 6 
leukaemogenic tyrosine kinases. 
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Summary 
There are a number of leukemogenic protein tyrosine kinases (PTKs) associated 
with leukaemic transformation. Whilst each is linked with a specific disease their 
functional activity poses the question whether they have a degree of commonality 
in their effects upon target cells. Exon array analysis of the effects of 6 
leukemogenic PTKs (BCR/ABL, TEL/PDGFRβ, FIP1/PDGFRα, D816V KIT, 
NPM/ALK and FLT3ITD) revealed few common effects on the transcriptome.  It is 
apparent, however, that proteome changes are not directly governed by 
transcriptome changes. Therefore, we have assessed and used a new 
generation of iTRAQ tagging, enabling eight-channel relative quantification 
discovery proteomics, to analyse the effects of these 6 leukemogenic PTKs. 
Again these were found to have disparate effects on the proteome with few 
common targets. BCR/ABL had the greatest effect on the proteome and had 
more effects in common with FIP1/PDGFRα.  The proteomic effects of the 4 type 
III receptor kinases were relatively remotely related. The only protein commonly 
affected was eosinophil-associated ribonuclease 7. Five out of 6 PTKs affected 
the motility-related proteins CapG and vimentin, though this did not correspond to 
changes in motility. However, correlation of the proteomics data with that from 
the exon microarray not only showed poor levels of correlation between transcript 
and protein levels, but also revealed alternative patterns of regulation of the 
CapG protein by different oncogenes, illustrating the utility of such a combined 
approach. 
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Introduction 
Human leukaemias are often associated with chromosome translocations which 
generate a fusion transcript that can be implicated in disease pathogenesis (for a 
review see (1)). Many of these translocation gene products encode for 
constitutively activated protein tyrosine kinases (PTKs). These include BCR/ABL 
(2), a PTK associated with Chronic Myeloid Leukaemia and TEL/PDGFRβ (3), 
observed in some cases of Chronic Myelomonocytic Leukaemia. FIP1L1-
PDGFRα fusion gene is associated with the pathogenesis of about 50% of 
patients with the hypereosinophilic syndrome (4). A t(2;5) translocation results in 
the fusion kinase NPM/ALK, found in cases of anaplastic large cell lymphoma 
(5). Recently other forms of PTK dysregulation have been observed in 
myeloproliferative disorders and the leukaemias: The Kit receptor PTK 
undergoes activating mutations (D816V) in acute myeloid leukaemia (AML) (6) 
and in solid tumors; internal tandem duplication at the juxtamembrane region of 
the flt3 gene is a somatic change detected in 20% of cases of AML that leads to 
enhanced ligand independent PTK activity in the FLT3 Internal Tandem 
Duplication (ITD) form of the protein (7). 
 
Targeted inhibition of the PTKs (such as KIT, BCR/ABL, TEL/PDGFRβ) via 
inhibitors that bind the ATP pocket of the kinase domain has been a successful 
strategy to achieve haematologic or molecular remission (8). In CML the use of 
Imatinib, a BCR/ABL kinase inhibitor, has profoundly altered approaches to 
treatment (9). However, after 5 years a significant proportion of patients develop 
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a resistance to the drug, although other molecular therapies remain effective 
(10). The requirement for further developments in treatment of this and other 
leukaemias is apparent and further detail of mechanisms for oncogenic tyrosine 
kinase-mediated  leukaemic transformation are required.  
 
The development of systems biology offers new opportunities for the study of 
oncogenic effects of genes deregulated in primary cells from patients with 
leukaemia. Investigation of protein levels in such cells is important as, in 
hematopoietic cells, changes in the levels of mRNA do not necessarily act as a 
predictor for changes in the proteome (11). The effects of the TEL/PDGFRβ 
oncogene on a haematopoietic cell line proteome have been shown to be driven 
by altered transcription plus post-translational regulation of protein levels (12). 
However, sensitive protein expression analysis has been problematic as 
amplification of protein, unlike DNA or RNA, cannot be achieved. Relative 
quantification proteomics using higher sensitivity mass spectrometry techniques 
now offers the potential to compare and contrast the effects of leukemogenic 
PTKs. Currently an isobaric tag-based methodology for peptide relative 
quantification (iTRAQ) coupled to multidimensional liquid chromatography and 
tandem mass spectrometry enables the assessment of protein levels where 4 
samples can be compared for their common effects (13).  Here we report the use 
of a novel 8 channel relative quantification mass spectrometry technique to 
compare the relative effects of 6 oncogenic tyrosine kinases, BCR/ABL, 
TEL/PDGFRβ, FIP1/PDGFRα, D816V KIT, NPM/ALK and FLT3ITD. The effects 
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of the oncogenes on the proteome are distinctive and do not follow normal 
oncogene classification patterns.  
 
 
Experimental Procedures 
Cell lines  
Ba/F3 cells were transfected with either an empty MSCV retroviral vector, or 
MSCV containing BCR/ABL, TEL/PDGFRβ, FIP1/PDGFRα, D816V KIT, 
NPM/ALK or FLT3ITD. The resultant cell lines were maintained in culture in 
Fischers (Invitrogen) with 10% (v/v) horse serum (Biowest, Nuaillé, France). 
Ba/F3-MSCV cells were grown in Fischers with 10% (v/v) horse serum 
supplemented with 5% mIL-3 (conditioned media from X63-Ag-653 cells).  
 
Microarray analysis 
RNA was prepared using TRIzol (Invitrogen), DNase treated then cleaned 
using MinElute RNeasy Clean up Kit (Qiagen) per manufacturers 
instructions. Transcriptome analysis was undertaken using murine 
GeneChip® Mouse Exon 1.0 ST Arrays by the CR-UK Affymetrix 
microarray facility (Paterson Institute, Manchester, UK; 
http://bioinformatics.picr.man.ac.uk/vice/Protocols.vice). All data were 
analysed in R using Bioconductor (14). Expression summaries were 
generated using RMA (15) with a custom Chip Definition File (CDF) file 
produced using the makecdfenvs library (Irizarry et al, unpublished). Fine 
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grained gene level annotation was provided using the X:MAP database 
(http://xmap.picr.man.ac.uk) and the exonmap BioConductor package 
(16). It is unreasonable to assume that a given gene should have the 
same baseline level of expression in each of the different cell lines or that 
the same level of response should be observed across all cell lines. 
Consequently, it is unreasonable to expect either the expression levels or 
fold changes to come from a single distribution. Thus each cell line was 
analysed separately, and the set of probesets exceeding a 2 fold change 
selected. Up- and down-regulated probesets were treated separately. For 
each probeset, the number of cell lines in which it was found to be up or 
down regulated was determined, and used to provide a score. Data were 
permuted in order to create a null distribution of these scores, from which 
the False Discovery Rate (FDR) (17) was estimated. The set of probesets 
found to be consistently differentially expressed in 6, 5 or 4 oncogene-
expressing cell lines were identified and then filtered using exonmap to 
exclude those that did not hit within an Ensembl (18)  annotated gene, or 
that hit the genome at more than one location. Remaining probesets were 
then mapped via exonmap to their target genes.  
 
Liquid chromatography and mass spectrometry 
Cell pellets were produced and processed as previously described (12) with 
minor modifications. In brief, cells were lysed in 1M triethylammonium 
bicarbonate (TEAB) with 0.1% (w/v) SDS. 50 µg of protein from each cell line 
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was reduced, alkylated, and subjected to tryptic hydrolysis prior to labelling with 8 
channel iTRAQ reagent (Applied Biosystems, Framingham, MA) in 1M TEAB, 
according to the manufacturer’s instructions (in all experiments labelling 
exceeded 98% of total identified peptides). Two biological replicates of MSCV 
Ba/F3 cells were labelled to provide an internal control for the experiment and 
assess biological variation. The entire experiment (including generation of cell 
pellets) was performed twice.  Peptides were fractionated off-line using an SCX 
cation exchange column (40 fractions) prior to RP-LC-MS/MS. Data were 
acquired using an independent data acquisition protocol where an MS scan was 
taken then the two highest abundance (ion current) ions were selected for 
fragmentation, followed by dynamic exclusion for 1 minute.  
 
Data Analysis 
Data was processed by a ‘Thorough’ search against a mouse CDS database 
(mouse_KBMS5_0_20050302, 115,660 entries) using the Paragon algorithm 
(19) within ProteinPilot v2.0 software with trypsin as the digest agent and default 
settings (Applied Biosystems, Warrington, UK). This software calculates a %age 
Confidence which reflects the probability that the hit is a false positive, so that at 
the 95% confidence level, there is a false positive identification rate of around 5% 
(19). While this software automatically accepts all peptides with a confidence of 
identification >1%, only proteins which had at least one peptide with >95% were 
initially recorded. These low confidence peptides therefore do not identify a 
protein by themselves, but may support the presence of a protein identified using 
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other peptides. Performing the search against a concatenated database 
containing both forward and reversed sequences (therefore 231,320 entries) 
allowed estimation of the false discovery level. 
 
For protein relative quantification, only MSMS spectra which were unique to a 
particular protein, and where the sum of the signal-to-noise ratio for all of the 
peak pairs is >9 were used for quantification (default software settings). The 
accuracy of each protein ratio is given by a calculated ‘error factor’ in the 
software, and a p-value to asses its whether the protein is significantly 
differentially expressed. Error factor is calculated as 10^(95% confidence error), 
where this 95% confidence error is the weighted standard deviation of the 
weighted average of log ratios multiplied by the Student t-factor for n-1 degrees 
of freedom, where n is the number of peptides contributing to protein relative 
quantification. P-value is determined by calculating Student t-factor by dividing 
(Weighted Average of Log Ratios– log Bias) by the Weighted Standard 
Deviation, allowing determination of the p-value, with n-1 degrees of freedom, 
again where n is the number of peptides contributing to protein relative 
quantification. For the identification of expression differences, each experimental 
run was initially considered separately. To be identified as being significantly 
differentially expressed, a protein had to be quantified with at least three spectra 
(allowing generation of a p-value), have a p-value<0.05, and have a ratio fold 
change >1.2 or <0.8 in both experimental replicates. These fold change limits 
were selected on the basis of our previous work with the four-plex iTRAQ reagent 
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(12), and were shown here to be equally applicable to the eight-plex iTRAQ 
relative quantification by the inclusion of internal controls (Figure 2D). 
 
Data was further analysed using Genespring GX microarray analysis package 
(Agilent Technologies). 
 
Western blotting and activity assays 
Western blotting was performed using standard protocols. Antibodies used were 
actin (1:500; Sigma, Poole, UK), CapG, (0.25µg/mL; Abcam, Cambridge UK), 
Abl, Flt3, Kit, PDGFRα (1µg/mL, 0.1µg/mL, 1µg/mL, 1µg/mL; Santa Cruz, Calne, 
UK), phosphotyrosine 4G10 (50ng/mL; Upstate, Milton Keynes, UK), PDGFRβ 
(1µg/mL; BD Pharmingen, Oxford, UK), NPM (neat hybridoma supernatent, LRF 
Diagnostics Unit, Oxford, UK).  
 
Quantitative real-time PCR analysis   
Primers and probes were designed using the Universal Probe Library Assay 
Design Centre from Roche Applied Sciences (https://www.roche-applied-
science.com/sis/rtpcr/upl/adc.jsp). Q-RT-PCR assays were performed in triplicate 
on a 7900HT Fast Real-Time PCR System. ∆∆Ct values were calculated for each 
sample against the average of the two housekeeping genes which were 
employed to calculate fold change using the 2-∆∆Ct method (20). 
 
Chemotaxis assays 
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Chemotaxis assays were performed as previously described (21) except that 
serum free StemSpan medium (Stem Cell Technologies, Vancouver, BC) was 
employed to preclude oncogene-mediated responses to serum associated 
agonists, and assays were carried out in 24 transwell plates with 5µm inserts 
(Sigma). 
 
Results 
A common cell population for relative analysis of PTK effects.  
The role of tyrosine kinases in leukaemogenesis is undisputed. The panoply of 
kinases involved suggests there could be common downstream targets and our 
aim was to systematically analyse several leukaemogenic protein tyrosine 
kinases. Six different leukaemogenic PTKs were expressed in a common Ba/F3 
background for this purpose (Figure 1A). Ba/F3 cells were chosen because of 
their widespread usage in studies on leukemogenesis. Each transfected cell line 
was shown to be independent of IL-3 for growth. Furthermore clones of each cell 
line that had the same doubling time as empty vector-transfected cells (MSCV 
Ba/F3) cultured in IL-3 were chosen (data not shown). Expression of the PTKs 
led to differential effects on protein tyrosine phosphorylation (Figure 1B). 
 
Comparative analysis of the effect of expression of leukaemogenic tyrosine 
kinases on the transcriptome  
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Genechip microarrays have been used extensively in the study of oncogene 
effects on the transcriptome. Exon arrays now allow a genome-wide, exon-level 
analysis on a single array to investigate alternative splicing and gene expression.  
 
RNA was produced from each cell line and the effects of the oncogene on the 
transcriptome assessed. The exon microarray data indicated that there were 
relatively few common changes (data can be found at 
http://bioinformatics.picr.man.ac.uk/vice/) at the gene level imposed on the Ba/F3 
cells by the 6 PTKs. Where up-regulation has occurred, 86 probesets (matching 
44 genes) showed changed levels (>2fold) in 6 out of 6 (6/6) oncogenes, with a 
further 311 probesets (194 genes) in 5/6 and 949 probesets (598 genes) in 4/6. 
Given the extensive nature of these arrays (i.e. the large number of probesets 
they contain), calculated false discovery rates (the proportion of probesets which 
would appear in each category by chance) are 75.4%, 55.5% and 48.1% 
respectively. Clustering exons to genes enables higher confidence of an effect. 
However, only 5 genes (comprising 33 probesets) show up-regulation of at least 
half of their exons in 6/6 oncogenes (Table 1).  
 
Analysis of the down-regulated genes shows a similar pattern. While down-
regulation appears to be more prevalent than up-regulation, still only 396 
probesets (from 117 genes) were significantly altered by 6/6 oncogenes, with 
1232 (391 genes) and 2742 (1110 genes) being down-regulated by 5/6 and 4/6 
oncogenes respectively. Again the nature of these experiments means a 
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calculated false discovery rates for these probesets of 17.5%, 22.2% and 22.7% 
respectively. Further analysis at gene level showed that only 12 genes 
(comprising 122 probesets) have two-fold (or greater) down-regulation of at least 
half of their exons in 6/6 oncogenes (Table 1).  
 
While a more in-depth analysis is in progress to detect variation in gene splicing, 
it remains clear from these data that the mode(s) of action of the six oncogenes 
being studied have very few common features at the transcriptome level. The 
lack of commonality at the transcriptome level does not exclude the possibility 
that these oncogenes do in fact share a common pathway for transformation, 
potentially via splicing. Further analysis of this dataset is underway to identify 
splicing effects of PTKs. 
 
We then considered other means for PTKs to elicit common effects. It is now well 
established that oncogenic tyrosine kinases, not only post-translationally modify 
proteins but also initiate post-translational regulation of the proteome via 
processes such as altered rates of translation, or stability via post-translational 
modification e.g. ubiquitination (22). Only analysis of proteomic changes can 
reveal these targets as mRNA levels will remain unperturbed. We have 
previously shown that oncogene-induced changes in the proteome do not always 
correlate to changes in the transcriptome (12). In addition changes seen in 
protein levels in primitive hematopoietic cells undergoing development do not 
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correlate precisely to changes in the transcriptome (11). We therefore 
investigated the effects of these oncogenes on the proteome. 
 
Isobaric tagging for relative quantification from 8 samples in a single mass 
spectrometry experiment. 
We have previously shown that the iTRAQ isobaric tagging approach gives 
highly reproducible data in the sense that peptides from the same protein show 
similar relative quantification patterns and also biological replicates show 
markedly similar trends (11, 12). A new generation of iTRAQ isobaric tagging 
reagent was employed for 8 channel peptide relative quantification proteomics. 
This employs the same chemistry to label peptides via free amine groups as 
previously described (13) but are constructed to enable 8 different samples to be 
relatively quantified in a single tandem mass spectrometry experiment (Figures 
2A and 2B). In the 8-plex reagent, reporter ion masses are now 113.1-119.1, and 
121.1. The mass at 120.1 is omitted, to avoid contamination from phenylalanine 
immonium ion (m/z 120.08). The extra channels are added by increasing the 
overall mass of the balance group. In addition, all mass differences are now 
encoded using 13C and 15N around a ring structure in the reporter group (Figure 
2A). A representative MS/MS spectrum showing the new reporter ion region is 
shown in Figure 2B.  
 
To ensure appropriate relative quantification using the new reagent, a defined 
protein mix was digested with trypsin and labelled with the 8 channel iTRAQ 
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reagent (Figure 2C) as previously described with the 4 channel iTRAQ reagent 
(12). The appropriate protein relative quantification levels were found to be 
achieved with the approach employed with the mixture of proteins (see legend to 
Figure 2). Analysis of a standard 8-protein mix shows that in all cases this 
method is capable of protein relative quantification (all proteins except 
ovotransferrin and carbonic anhydrase were present in a 1:1 ratio in the 
isobarically tagged tryptic digest samples, see figure legend for detail). It should 
be noted that, in our hands, the approach slightly underestimated the degree of 
fold change anticipated, shown by the diamond symbols (Figure 2C), a feature 
we have previously observed with the 4-plex reagent. These data show that the 
8-plex iTRAQ can be employed for assessment of relative PTK effects on the 
proteome. 
 
Comparative analysis of the effect of expression of leukaemogenic tyrosine 
kinases on the proteome  
To analyse potential common proteome differences elicited by the 6 PTKs, eight 
channel isobaric tagging with tandem mass spectrometry was employed. 
Proteomics data was obtained from two experiments where 1380 protein and 
1614 protein identifications with a confidence score greater than 95% were made 
respectively. Searching against a reversed database allowed calculation of false 
discovery rates for these two experiments as 0.146% and 0.806% at the protein 
level respectively. Relative quantitation analysis was performed on these 
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datasets separately and then averaged together to give a list of 1886 proteins 
(See supplementary Table 1).  
 
In each case, labelling efficiency was estimated to be >98%, by comparing the 
total number of identified potential reactive sites (i.e. N-termini and lysine side 
chains) with the number of iTRAQ modifications at these sites. In addition, there 
was some concern that, although the total amount of protein analysed in the 8-
plex experiment was the same as in a standard 4-plex (i.e. 400µg), there is now 
only half of the material in each channel (50µg per 8-plex, compared to 100µg 
per 4-plex). However, we compared the number of peptides identified with 
confidence >90% in this dataset and a 4-plex dataset from similar samples (i.e. 
whole cell lysates), and showed that in each case around 8% of these peptides 
were not included in the final dataset due to low iTRAQ reporter ion intensity. 
Therefore there appears to be no deleterious effects of halving the amount of 
sample in each channel to allow expansion from a 4-plex to an 8-plex relative 
quantification experiment. 
 
Further analysis was performed to select proteins where there was a high 
confidence of protein identification and relative quantification using criteria 
defined in the analysis software (see Methods and legend to Supplementary 
Data Table 2). Relative quantification of the effects of 6 PTK oncogenes on 829 
proteins is therefore shown where two channels were biological replicates of 
mock-transfected Ba/F3 cells, included to confirm reproducibility of the approach 
 15  
 at SM
AC Consortium
 - University of Zürich on February 5, 2010 
w
w
w
.m
cponline.org
D
ow
nloaded from
 
as was seen in our previous work  (11, 12). Figure 2D shows the ratio for the 
majority of proteins lies between 0.8 and 1.2, the window previously described 
(12) beyond which a protein can be considered to be potentially changed in 
expression level. For comparison the relative protein expression levels of 
oncogene-transfected Ba/F3 cells compared to MSCV Ba/F3 are shown (Figure 
2E-2J). These demonstrate the quantitative variability in the effect of each 
oncogene on the proteome as a whole, BCR/ABL having the largest gross effect.    
 
The changes noted for the oncogenes in both experimental replicates were: 
BCR/ABL (168 proteins changed, 77 down, 91 up), TEL/PDGFRβ (67 proteins 
changed, 22 down and 45 up), NPM/ALK (87 proteins changes, 59 down, 28 up), 
D816V KIT (106 proteins changes, 54 down, 52 up), FLT3ITD (73 proteins 
changes, 38 down, 35 up), and FIP1/PDGFRα (124 proteins changes, 43 down, 
81 up). The identities of these proteins are shown in Supplementary Data Tables 
3-8. 
 
Protein changes were examined further using a dendrogram approach to identify 
any clustering of oncogene effects. The analysis showed neither clustering of 
type 3 leukaemogenic receptor tyrosine kinases (FLT3ITD, D816V KIT, 
FIP1/PDGFRα, TEL/PDGFRβ) nor oncogenes associated with myeloproliferative 
disorders (Figure 3A). D816V KIT did cluster with FLT3-ITD but this was in a 
group of 3 with NPM/ALK, the only PTK in the set associated with lymphoma. 
Construction of an Edwards-Venn diagram containing proteins with a change in 
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expression between control cells and each oncogene-transfected cell population 
also revealed the lack of major overlap in effect between any of the oncogenes 
(Figure 3B). Surprisingly, FIP1/PDGFRα and TEL/PDGFRβ oncogenes showed 
very little similarity. We therefore conclude that leukaemogenic tyrosine kinases 
have pleiotropic effects on global protein expression. This is underscored by 
analysis of the gene ontogeny for proteins affected (in expression level) by the 
oncogenic PTKs in that effects on many protein groups were recorded and the 
effects of each oncogene were broadly similar (data not shown).  
 
The number of proteins within the dataset affected by >4 of the oncogenic PTKs 
was small (Table 2) and covers a wide variety of protein functions. Eosinophil 
associated ribonuclease 7 is a member of the RNase A superfamily involved in 
inflammatory processes mediated by eosinophils.  CapG binds the end of actin 
filaments and regulates cellular structure (23). Scinderin (adseverin) cleaves 
actin filaments and has previously been shown to be changed in expression in 
the hematopoietic stem cell to progenitor cell transition (24). Vimentin is a 
member of the intermediate filament family of proteins that is increased in 
expression with all PTKs except FIP1/PDGFRα.  Two related protein 
phosphatase inhibitors (SET proteins) are decreased in 4/6 and 5/6 PTK 
transfected cell lines respectively, D816V KIT cells being the only cells to show 
no change in either. These proteins have been implicated in BCR/ABL mediated 
transformation (25, 26). The two 40S ribosomal proteins S2 and S15 both display 
an increase except with the TEL/PDGFRβ and NPM/ALK transfected Ba/F3 cells. 
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This relative lack of common effects demonstrates diversity in mechanism of 
action for leukaemogenic PTKs. 
 
Correlation of peptide expression data to exon expression data 
In the past, comparison of protein expression data to transcript expression has 
been achieved, but is always undermined by the inability of both standard 
expression array platforms and bottom-up proteomics analyses to accurately 
resolve different isoforms. We have established novel bioinformatic approaches 
to link this proteomic data to the exon array data to check the correlation 
between protein/peptide abundance and mRNA expression. This enables 
analysis of oncogenic PTK effects on splice isoform generation. We can now 
assess the correlation of proteome to transcriptome at three levels: peptide to 
exon probesets; >1 peptide to exon data; protein expression (summated peptide 
data) versus gene specific expression (summed exon data). Pearson correlation 
between exon arrays and peptide data, at the exon vs. peptide level, for MSCV 
versus oncogene was: 0.47 for BCR/ABL; 0.22 for NPM/ALK; 0.28 for 
TEL/PDGFRβ; 0.30 for FLT3ITD; 0.25 for D816V KIT and 0.40 for 
FIP1/PDGFRα. The data set will be the subject of a much more in depth analysis 
(manuscript in preparation) but the main conclusion relevant here is that there is 
relatively poor correlation between changes at the exon and peptide levels. Thus 
a majority of protein changes cannot be predicted by mRNA analysis. Selected 
examples of this correlation and its anomalies are illustrated in Figure 4 where 
protein expression data for proteins shown in Table 2 has been compared to 
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exon array data. The transcriptome and proteome expression levels for Ribose-
5-phosphate isomerase and eosinophil major basic protein show a high degree 
of correlation. The data for CapG however clearly demonstrates that the data 
obtained from RNA expression levels does not always correlate to protein 
expression levels. The fidelity of the exon array and iTRAQ data was confirmed 
by use of QRT PCR and western blot analysis. The data for CapG also illustrates 
that different oncogenes can affect a protein/pathway by different mechanisms. 
Whilst CapG is down-regulated in both NPM/ALK and BCR/ABL transfected cells 
this occurred via different mechanisms: NPM/ALK cells showed a decrease in 
transcript level resulting in a similar decrease in protein level; BCR/ABL cells 
display no decrease in transcript yet protein levels are decreased.  
 
 
Correlation of proteomic changes to motility effects. 
Systematic proteomic analysis enables oncogenic effects on specific functional 
pathways to be assessed and further analysis performed. The oncogene-
transfected cell lines were shown to display differential cell motility in serum free 
conditions (Figure 5). In cells expressing BCR/ABL motility is decreased, as 
observed in previous studies (27, 28). However, expression of TEL/PDGRFβ in 
these conditions enhanced motile response as did D816VKIT. Vimentin, 
scinderin and CapG are proteins associated with the cytoskeleton and motility 
that are affected by almost all of the 6 PTKs in this analysis. Thus their 
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modulation by oncogenic PTKs can be seen to be inconsistent with the 
differential effects observed on motile response. 
 
 We therefore further analysed the data for all proteins affected by each PTK 
whose gene ontology suggests association with motility. Within this set were 
proteins that were perturbed (increased or decreased) in expression levels by 
BCR/ABL and perturbed in the opposite direction by TEL/PDGFRβ and 
D816VKIT.  Two candidates were found that could affect motile responses. 
These were High mobility Group protein B2 (HMGB2) and Septin 1. HMGB2 has 
previously been associated with altered motility and is therefore a candidate 
target protein for altered motile responses instigated by these oncogenes.  
 
 
Discussion 
The discovery of PTKs that are associated with leukaemogenic transformation 
have led to investigation of the specific roles for these kinases in transformation 
(29-31). Often a singular oncogenic PTK is the subject of a focussed study 
seeking to identify downstream effectors modulated by that specific kinase, such 
as motility effects or genomic stability mediated by BCR/ABL (32, 33). The 
molecular components of any oncogene-mediated change are then targets for 
analysis in respect of the effects of other PTKs: much information exists 
describing the effects of BCR/ABL on a variety of pathways and processes (34, 
35) but a much less substantial scientific literature has developed on the effects 
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of other oncogenic kinases on these pathways. In this fashion the determination 
of common and uncommon events promoted by specific kinases will progress at 
a relatively slow rate. Given the growing number of kinases associated with the 
leukaemias we have sought to establish whether novel systems biology 
approaches can determine the effects of PTKs on the proteome and 
transcriptome.  
 
To achieve a meaningful foundation dataset the requirement is for a common 
cellular background on which to examine the effects of PTKs. Ba/F3 cells are 
commonly employed in studies on leukaemogenesis and are therefore suitable 
for initial analyses (36). Whilst this approach demands follow up studies on other 
cell lines and primary material, a successful primary screening strategy on a 
common background will inevitably save time in understanding common events 
seen in transformation.  
 
The analysis of the dataset we have constructed has shown very few common 
leukaemogenic PTK mediated events. At the exon/transcript level, these include 
increases in hepatocellular carcinoma associated antigen, LR8 protein and CD55 
antigen. CD55, an inhibitor of the complement system, is widely expressed in 
malignant tumours and reported to have a role in decreasing complement 
mediated tumour cell lysis, cell motility and metastasis (for a review see (37)). 
Other probesets also showed changes in 6/6 oncogenes, but these were 
accompanied by no changes in other exons from that gene. This may represent 
 21  
 at SM
AC Consortium
 - University of Zürich on February 5, 2010 
w
w
w
.m
cponline.org
D
ow
nloaded from
 
alternative splicing events. However, given the large number of probesets on 
each array (over 1.4 million probesets) it is almost inevitable that many false 
positives will be called ‘changed’ and that a subset of these will be called in all 
oncogenes by random chance. The false discovery rates for identification of an 
up-regulation in 6/6 oncogenes suggests that 75.4% of those identified could be 
expected by chance. We reasoned that, since this analysis is done at the 
probeset level, those probesets which are falsely called ‘changed’ in 6/6 
oncogenes will be unlikely to map to the same gene locus by random chance. 
So, in this background only genes which had a large proportion of its probesets 
shown to be altered in all oncogenes can be reported as potential common 
targets. Unfortunately, the protein products of these genes were not identified in 
the proteomic analysis, presumably due to their low abundance. Data generated 
using exon arrays offers the opportunity to consider the possible effects of 
transformation by individual oncogenes on splice variants and gene expression. 
Further analysis on exon specific effects to consider oncogene-mediated splice 
variant generation is underway.   
 
It is now becoming more accepted that changes in the proteome do not 
necessarily occur as a result of changes in transcription. To look for common 
oncogenic targets in the proteome, we utilised the newly developed 8 channel 
iTRAQ reagent to simultaneously assess protein expression in cells expressing 
six different oncogenes, with the remaining two channels taken up by biological 
replicates of empty vector-transfected cells. The 8 channel iTRAQ system is a 
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redesigned version of the 4-plex reagent to allow incorporation of the extra 
isotopes required to extend the reporter ion mass range. This requires a new 
‘balance’ group and minor modifications to the reporter, while retaining the same 
labelling chemistry via an NHS-ester. In our hands, this new reagent retains 
many of the features of the 4-plex reagent in that labelling efficiency remains 
high, we see an apparent increase in signal in a UV detector (at 214nm) during 
SCX fractionation, and peptides appear to have slightly increased retention on 
SCX. There is no evidence that peptide elution is different for peptides labelled 
with different iTRAQ reagents (on either SCX or RP media), peptide 
fragmentation is good and the iTRAQ reporter ion signal(s) are generally among 
the most abundant peaks in the majority of spectra. Using a defined mixture, we 
have shown that, like the 4-plex, the 8-plex is capable of detecting differences in 
peptide levels between two samples but the degree of change is underestimated. 
This is unimportant in a study where a low false positive rate is required, as in 
our studies. We have therefore demonstrated that 8 channel relative 
quantification mass spectrometry can compare protein profiles (and in the future 
phosphopeptide profiles (38) in hematopoietic cells).  
 
Once again, however, the proteomics analysis supported the hypothesis that the 
leukaemogenic properties of the six oncogenes shared little in common. Only 
one protein was shown to be affected by all six oncogenes, namely eosinophil-
associated ribonuclease 7 (also known as ribonuclease 7). Other proteins found 
to be altered in 5/6 or 4/6 oncogenes include two members of the SET protein 
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phosphatase family (I2PP2A and Acidic nuclear phosphoprotein pp32). This 
protein is known to be involved in BCR/ABL-positive chronic myeloid leukaemias 
(25). Also, several proteins identified are related to the actin cytoskeleton 
structure. This would suggest a common effect on cell shape or cell motility. 
Functional assays for motility suggests that, while BCR/ABL appears to decrease 
the motile response the SDF1, and both TEL/PDGRFβ and D816VKIT increase 
motility, this pattern does not correlate with the change in expression of these 
proteins. Likewise, further analysis of the data for proteins whose expression 
follows this pattern yields two candidates, Septin 1 and HMGB2. These are both 
therefore candidates for proteins which play a role in oncogene-mediated 
alterations in motility. However, it is clear that, since other motility associated 
proteins remain unaltered, or do not follow this pattern, that the oncogenes which 
do affect motility probably do so using distinct mechanisms. 
 
The exon array approach has been coupled to proteome analysis to match 
relative quantification at the peptide and exon probeset level. This analysis is 
potentially more powerful that a gene versus protein analysis due to the methods 
of data generation.  Standard proteomics and microarray technologies each may 
sample different parts of a protein transcript, so it could be that a comparison is 
actually between probesets at the beginning of a transcript, versus peptides from 
the end of the protein. This may be reason why proteome and transcriptome 
changes correlate poorly in previous studies. Using exon arrays allows a much 
higher resolution mapping, matching peptide expression to the levels of the 
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mRNA from the exon which codes for it. However, this analysis also shows a 
general lack of correlation between changes in expression at the transcript and 
proteome level. Interestingly, the correlations between protein and gene, were 
better than those between peptide and exon (data not shown), presumably 
because averaging peptides/exons reduces the effect of outlying data points. To 
confirm these data for a case where there was no correlation, CapG, the 
proteome and transcriptome data were checked using western blotting in relative 
quantitative PCR respectively. This confirmed the accuracy of the systematic 
analyses, and also revealed further differences between the actions of the 
oncogenes. Where both NPM/ALK and D816VKIT downregulate CapG by 
decreasing the rate of mRNA transcription, BCR/ABL, FLT3-ITD and 
FIP1/PDGFRα all show no change in CapG mRNA levels, and therefore 
downregulate the protein either by slower rate of translation or by increased 
degradation.  These findings promote the idea that proteome analysis (at both 
the protein and peptide and phosphopeptide level) should be a key element of 
systematic analyses of oncogene effects.  
 
Here we have shown that simple extension of effects seen with one PTK to other 
leukaemogenic oncogene tyrosine kinases is inappropriate. There is little 
correlation between 6 PTKs on the proteome seen using the approach we have 
validated here. Rather than deflecting the search for commonalities the study 
suggests a focus on specific organelles (to identify common effects on lower 
abundance proteins) and enrichment of post-translationally modified proteins as 
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a target for further analyses. The present analysis shows no correlative links 
between type III receptor kinase effects, few common effects elicited by 6 PTKs, 
a raft of effects across many gene ontology groups and a group of proteins 
commonly affected that therefore enable development of ideas on common 
events required in PTK action that contribute to transformation. 
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Table One. Genes identified as changing in all 6 oncogenes on analysis of the 
exon array data. To be included the genes must change greater than 2 fold in 
over half of the probe sets. *Denotes where probesets associated with this gene 
locus but not mapped to an exon are also changed by >2-fold. 
Genes up-regulated in all 6 cell lines (greater than 2 fold) 
Id Gene description Probesets changing  
(total number of exonic 
probesets) 
ENSMUSG00000023367 Hepatocellular carcinoma-
associated antigen 112 
5 (8) 
ENSMUSG00000029810 LR8 protein 8 (10) 
ENSMUSG00000031773 cDNA sequence AK220210 17 (28) 
ENSMUSG00000026399 CD55 antigen 7 (10) 
ENSMUSG00000057596 Expressed sequence AI451617 4 (6) 
Genes down-regulated in all 6 cell lines (greater than 2 fold) 
ENSMUSG00000018924 Arachidonate 15-lipoxygenase 14 (15) 
ENSMUSG00000034652 CD300A antigen 11 (11) 
ENSMUSG00000019122 Chemokine (C-C motif) ligand 9 8 (9) 
ENSMUSG00000030483 Cytochrome P450 2b13 6 (10) 
ENSMUSG00000032089 Interleukin 10 receptor, alpha 13 (11)* 
ENSMUSG00000029446 Phosphoserine phosphatase 7 (9) 
ENSMUSG00000021108 Protein kinase C, eta 16 (17) 
ENSMUSG00000027073 Proteoglycan 2 5 (7) 
ENSMUSG00000054366 RIKEN cDNA A330102H22 5 (10) 
ENSMUSG00000040302 RIKEN cDNA C030048B08 6 (10) 
ENSMUSG00000010342 Tex14 21 (37) 
ENSMUSG00000040828 Tmem146 10 (13) 
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Fold change  (Oncogene compared to control) 
Accession 
number Identity BCR/ABL TEL/PDGFRβ NPM/ALK KIT D816V FLT3-ITD FIP/PDGFRα 
Number of 
oncogenes 
change 
seen in  
trm|Q9R126 Eosinophil-associated ribonuclease 7 0.12 0.38 0.06 0.04 0.17 0.32 6 
spt|P20152 Vimentin  1.42 1.63 1.90 1.20 1.43 1.13 5 
spt|Q9EQU5 SET protein (Phosphatase 2A inhibitor I2PP2A)  0.74 0.68 0.77 0.96 0.80 0.85 5 
trm|Q99LB4 Capping protein  (CapG) 0.51 0.91 0.74 0.51 0.67 0.61 5 
trm|Q69Z71 Scinderin  0.26 1.48 0.60 0.39 0.41 0.25 5 
spt|P25444 40S ribosomal protein S2 (S4) 1.52 1.00 1.02 1.21 1.24 1.29 4 
spt|P62843 40S ribosomal protein S15 (RIG protein)  1.36 0.97 0.98 1.21 1.18 1.27 4 
spt|P47968 Ribose-5-phosphate isomerase  0.56 1.07 0.71 0.68 0.58 0.93 4 
trm|Q69ZN0 Guanine deaminase 0.46 0.79 1.27 0.54 0.55 1.31 4 
spt|Q61878 Eosinophil granule major basic protein precursor 0.15 0.47 0.47 0.21 0.32 0.23 4 
spt|O35381 Acidic nuclear phosphoprotein pp32 0.75 0.95 0.61 0.88 0.79 0.75 4 
cra|mCP22728.2 Ferritin light chain 1  0.48 0.83 0.39 0.44 0.44 0.53 4 
trm|Q8CJ71 Heterogeneous nuclear ribonucleoprotein 0.73 0.97 0.79 0.70 0.80 0.90 4 
trm|Q9D154 Serine protease inhibitor EIA 0.34 1.34 0.65 0.31 0.71 2.03 4 
 33  
Table 2.  Proteins whose expression is altered by the expression of four or more oncogenes. 
Proteins shown are those where a confident assessment of a common decrease or increase in 4 or more of the 6 
oncogenes has been found. To be included the data must contain more than 2 peptides and have a fold change (control 
versus oncogene) <0.8 or >1.2  with a  p-value of less than 0.05. The significant changes are shown in bold, the 
underlined values represent ‘changes’ where the confidence levels have not been met.  
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FIGURE LEGENDS 
 
Figure 1.  Retroviral expression of oncogenes in Ba/F3 cells. 
Ba/F3 cells were transfected with MSCV retroviral vector containing the different 
oncogenes as indicated. A) following drug selection the successful transfection 
was confirmed by assessing oncogene expression by western blot analysis on 
whole cell lysates. B) the effect of oncogene expression on the phosphotyrosine 
protein content of the cell was assessed by western blot analysis with anti-
phosphotyrosine antibody.  
 
Figure 2.  Analysis of protein expression in 6 oncogene transfected cell 
lines by 8plex isobaric tagging 
A) A schematic of the new 8-channel (8-plex) iTRAQ reagent, including the 
isotope coding in the new reporter groups. Reporter masses are sequential, but 
omit 120Da as this is also the mass of a phenylalanine immonium ion.  B) an 
example of the data generated is shown in with sequence determined by the 
pattern of fragment ions (lower panel) and quantification derived for the 
intensities of the 8 reporter ions (upper panel; sample relative abundance 
1:1:1:1:1:1:1:1). C) relative quantification of a mixture of 8 proteins mixed in 
predetermined quantities prior to isobaric tagging. The relative ratios in which the 
proteins were mixed is shown on the figure using diamond symbols. The bars 
shown represent 95% confidence interval levels. D) further validation of the 
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method using biological sample replicates is shown where the ratios of the 
MSCV:MSCV Ba/F3  control cells (mixed 1:1 ratio) were labelled and compared 
for protein ratios assessed using the iTRAQ approach. The x-axis indicates the 
protein identification score (Unused score from ProteinPilot software, see 
Methods) which represents the sum of the log10(%age confidence of peptide 
identification) of each unique peptide associated with only that protein. Each spot 
represents a protein, and only proteins with a score of >4 are included.  E-J) 
show the MSCV Ba/F3 cells isobaric tag relative quantification plotted against 
oncogene PTK transfected Ba/F3 cells.  
 
Figure 3.  Analysis of potential oncogene relationships 
A) Dendrogram analysis was performed using the condition tree option in the 
Genespring GX microarray analysis package (Agilent Technologies). Oncogenes 
are clustered according to similar protein expression profiles observed in iTRAQ 
ratios. Green indicates a decrease, red an increase and black indicates no 
change in iTRAQ ratios. The dendrogram tree structure illustrates the relationship 
between the oncogenes. The varying length of the horizontal “branch” indicates 
degree of similarity between the oncogenes-a shorter branch indicates a greater 
degree of similarity. B) An Edwards-Venn diagram constructed to illustrate the 
protein changes commonly caused by the oncogenes.  
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 Figure 4. Correlation of iTRAQ and exon array data 
Representative examples of proteins found to change in greater than 4 out of 6 
oncogenes are shown. Exon array, iTRAQ, western blot and QRT PCR data is 
displayed as a fold change compared to MSCV control.  
 
Figure 5. The effect of oncogenic PTK expression on the chemotactic 
response to SDF-1.  
The SDF-1 induced chemotactic response of Ba/F3 cells transfected with the 
oncogenes shown was assessed in Boyden chamber assays. 105 cells were 
added to the top well and 100ng/ml SDF-1 to either the top well, bottom well or 
both wells. The number of cells in the bottom well was counted after 6 hours. 
Results are the mean ± SEM of three experiments. 
 36  
 at SM
AC Consortium
 - University of Zürich on February 5, 2010 
w
w
w
.m
cponline.org
D
ow
nloaded from
 
SUPPLEMENTARY DATA 
 
Figure legend for Supplementary Table 1 – Table showing all 1886 proteins 
identified across two replicate analyses of Ba/F3 cells transfected with 6 
oncogenic PTKs. The first column denotes the database from which the protein 
sequence was obtained, along with its accession number. Columns 2 and 3 show 
the Unused protein score for that protein from each of the two experimental runs. 
The fourth column contains that name of the protein in that database, and the 
remaining columns show the (average) ratio of that protein in the oncogene 
transfected cells compared to an empty-vector control. Since the empty vector 
control was included twice in the experiment, the control:control ratio is always 
given. 
 
Figure legend for Supplementary Table 2 - Table showing all 829 high quality 
relatively quantified proteins from two replicate analyses of Ba/F3 cells 
transfected with 6 oncogenic PTKs. To be included in this table, a subset of the 
data shown in Supplementary Table 1, the protein had to be identified with an 
Unused protein Score of >2, quantification calculated from at least three spectra, 
and has a calculated error factor of <2. Column headings are as Supplementary 
Table 1 
 
Figure legend for Supplementary Table 3 - The high quality proteins identified 
to be differentially expressed between a control cell line and a BCR/ABL 
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expressing cell line. Column headings are as described in the legend to 
Supplementary Data Table 1. 
 
Figure legend for Supplementary Table 4 - The high quality proteins identified 
to be differentially expressed between a control cell line and a TEL/PDGFRβ 
expressing cell line. Column headings are as described in the legend to 
Supplementary Data Table 1. 
 
Figure legend for Supplementary Table 5 - The high quality proteins identified 
to be differentially expressed between a control cell line and a NPM/ALK 
expressing cell line. Column headings are as described in the legend to 
Supplementary Data Table 1. 
 
Figure legend for Supplementary Table 6 - The high quality proteins identified 
to be differentially expressed between a control cell line and a D816V KIT 
expressing cell line. Column headings are as described in the legend to 
Supplementary Data Table 1. 
 
Figure legend for Supplementary Table 7 - The high quality proteins identified 
to be differentially expressed between a control cell line and a FLT3ITD 
expressing cell line. Column headings are as described in the legend to 
Supplementary Data Table 1. 
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Figure legend for Supplementary Table 8 - The high quality proteins identified 
to be differentially expressed between a control cell line and a FIP1/PDGFRα 
expressing cell line. Column headings are as described in the legend to 
Supplementary Data Table 1. 
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Figure 2B
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Figure 2D
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Figure 3A
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